NEW YORK--(BUSINESS WIRE)--Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced the completion of an open-source connector linking Apple® ResearchKitTM with the Medidata Clinical Cloud® platform. This mechanism will enable life sciences companies and academic institutions to map data generated by ResearchKit apps into Medidata’s secure, regulatory-compliant environment, integrating the data with other information collected in clinical trials.
Medidata has released the source code for the connector on GitHub®, the world’s largest open source community, enabling life sciences researchers to create connections between ResearchKit apps and the Medidata platform. In doing so, Medidata is furthering efforts to accelerate drug development by helping clinical trial sponsors-and their contract research organization partners-gather more and better data on patients’ health status and response to therapeutic interventions.
“Apple is a key part of the ecosystem that defines the new era of mobile health. We’re excited that they are leveraging their market and technology leadership to help collect high-quality research data,” said Glen de Vries, Medidata’s president. “ResearchKit provides a terrific approach for dealing with the ‘last mile’ for in-life data, and linking ResearchKit-based apps to the Medidata Cloud means that studies can now be planned and managed on our integrated platform, where virtually every possible source of clinical data can be automatically integrated-regardless of whether the source is a healthcare professional or a patient, and regardless of whether the data was gathered in a clinic or the patient’s home.”
ResearchKit, Apple’s open-source framework that enables developers and researchers to create apps for medical research, brings together rich sets of personal data from iOS apps. To further the impact that this data can have in clinical research, Medidata has developed a mechanism allowing study builders to map the data generated from ResearchKit apps to studies in Medidata Rave®. Facilitating data capture and flow-as well as the incorporation of third-party lab and medical record data-directly into the Medidata Clinical Cloud, this initiative is part of Medidata’s ongoing efforts to unify mobile health devices with cloud-based technologies in a clinical trial setting.
“Making this open-source connector to ResearchKit available is consistent with everything we’ve done with our platform to date in order to integrate direct-from-patient data with traditional clinical data and provide a more holistic view of patients’ response to therapy and progression of disease,” said Mike Capone, Medidata’s chief operating officer. “As a company, Medidata is deeply committed to leveraging innovative technologies to make the science of drug development better, and we believe that initiatives such as this will result in better data, enhanced patient experiences and more efficient trials.”
Tecentriq Falls Short in Phase III Trial in Post-Surgery Triple-Negative Breast Cancer Patients
February 6th 2025In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative breast cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.